Aisha I Abdullah PhD,  —

Women with primary Sjögren’s syndrome experience more negative stressful life events than healthy people in the year before symptom onset, and the number of these negative events is associated with more severe disease activity, a study has found. “These results suggest that we…

Most patients with Sjögren’s syndrome and other rheumatic diseases develop antiviral antibodies after their first COVID-19 vaccine shot, but their treatment affects the chances of them developing antibodies, a recent study has found. In particular, an antibody response was significantly less likely in patients receiving…

The Sjögren’s Foundation has developed clinical practice guidelines for healthcare providers to improve the diagnosis, evaluation, and care of Sjögren’s syndrome patients with lung manifestations. The guidelines, which include 52 recommendations for Sjögren’s evaluation and…

A variant of the LILRA3 gene may be associated with greater lymphoma susceptibility in a group of Sjögren’s syndrome patients with disease onset prior to age 40, a study reports. The variant could be a potential biomarker of…

In observance of Sjögren’s Awareness Month in April, the Sjögren’s Foundation is inviting individuals with to share their stories to help raise awareness about this complex condition. This year’s theme, “Coming Together to Conquer Sjögren’s,” will showcase the many Faces of Sjögren’s and illustrate…

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to an application for Esbriet (pirfenidone) as a treatment for unclassifiable interstitial lung disease (UILD). The supplemental new drug application was submitted by Genentech, Esbriet’s developer and a member of the Roche Group, based on…

Tocilizumab, a medicine approved for certain types of arthritis, may be a safe and effective approach for treating severe respiratory distress associated with COVID-19 in people with autoimmune conditions, the case of an elderly Sjögren’s syndrome patient suggests. The report, “…

People with Sjögren’s syndrome and other systemic autoimmune rheumatic diseases (SARDs) may be at a greater risk of severe complications from COVID-19 than people without these disorders, a study reports. Specifically, SARDs patients are more likely to develop venous thromboembolism (VTE), or blood clots in…

RSLV-132, an investigational treatment for autoimmune conditions, led to significant and clinically meaningful reductions in patient-reported fatigue in people with primary Sjögren’s syndrome, results from a Phase 2 clinical trial show.